Eydenzelt receives FDA approval for four retinal diseases
diabetic macular edema

Eydenzelt receives FDA approval for four retinal diseases

Eydenzelt is approved for use in treating wet age-related macular degeneration, macular edema following reetinal vein occlusion, diabetic macular edema and diabetic retinopathy.
Cancer drug may also be a possible treatment for age-related macular degeneration
intravitreal injections

Cancer drug may also be a possible treatment for age-related macular degeneration

Clinical trials are set to launch later this year to evaluate whether the cancer drug, PRL3-zumab, is effective in treating wet age-related macular degeneration (AMD) as well as diabetic retinopathy.